![]() |
|
|
Forward to a colleague |
||
Access Full Stories Agilent has signed a definitive agreement to acquire automation expert Velocity11 for an undisclosed amount to enable it to speed up drug discovery and genomics research... Read The sweet taste of analysing biological drugs Researchers from Amgen have published results detailing a method that improves the analysis of the sugar groups attached to monoclonal antibodies (MAbs) and proteins... Read Product news in brief - week 45 LabTechnologist.com brings you its periodic round up of product news, with new releases from Affymetrix, Agilent, AnaSpec, Applied Biosystems, Axiom, Bio-Rad, KD Scientific, Millipore and Oxoid... Read Biomarker market predicted to 'explode' The global market for biomarkers is expected to more than double over the next 5 years to reach an estimated $12.8bn (€8.7bn), according to a new market research report... Read 'World's first' NanoImaging service centre opens NanoImaging Services has opened what it claims is a first of its kind first fee-for-service imaging business to enable structural characterisation and validation of biological drugs throughout the development... Read |
||||||||||||||||||
All News Headlines for: November | October | September |
||||||||||||||||||
ZIC®-HILIC Separation of Polar and Hydrophilic Compounds The technology leading ZIC®HILIC and ZIC®-pHILIC separation media, designed forpolar and hydrophilic compounds, are tools for clinical analysis and to solve separationand purification problems in research, development and production of pharmaceuticals.ZIC®-HILIC... Click Here | ||||||||||||||||||
|
Related Industry News Good news follows bad news for InVentiv After losing a key Novartis contract and getting caught up in the Inyx collapse, Inventiv Health had good news this week when it reported its third quarter results... Read Add PEG to make the drug go farther A US research team has found a way to increase drug distribution in the brain to fight the recurrence of human brain tumours... Read DSM third quarter results DSM's third quarter financial results are paving the way for the company's transition to a life sciences and material sciences company... Read Merck flexes muscle with GTx deal Merck & Co has inked a deal potentially worth over €507m (€346m) with GTx over a new class of drugs to treat muscle loss conditions, especially those caused by cancer... Read
|
||||||||||||||||||
|
|||||
Forward to a colleague |
|||||
To continue to receive this newsletter in your inbox, please add newsletter@LabTechnologist.com to your address book |
||
Update preferences | Change your email address | Unsubscribe |
||
Contact us: Advertising | Recruitment | Privacy policy | Terms & conditions | Feedback |
||
| © 2007 - Decision News Media S.A.S - All Rights Reserved Le Belem - 355, rue Vendemiaire - 34000 Montpellier - France http://www.decisionnewsmedia.com |
||